Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1

NCT02799095 is registered in ClinicalTrials.gov with Mural Oncology, Inc as lead sponsor.

NCT NCT02799095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02799095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1
Lead sponsor
Mural Oncology, Inc
Phase
Phase 1/2
Overall status
Completed
Start date
September 14, 2016
Completion date
August 2, 2023
Enrollment
243 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors